St. Jude Beats Estimates, With 'Small Impact' From Boston Sci Absence

St. Jude Medical's better-than-expected first quarter benefited from Boston Scientific's month-long hiatus from the U.S. implantable defibrillator market, but that was not the pivotal factor, according to the company